CYLD Protein — Lysine-Specific Deubiquitinase in Neurodegeneration

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

CYLD (Cylindromatosis Lysine Specific Deubiquitinase) is a unique tumor suppressor deubiquitinase that specifically cleaves Lys63-linked and linear polyubiquitin chains from substrate proteins. Originally identified as the gene mutated in familial cylindromatosis, CYLD has emerged as a critical regulator of multiple signaling pathways with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)). [@kovalenko2003]

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

CYLD (Cylindromatosis Lysine Specific Deubiquitinase) is a unique tumor suppressor deubiquitinase that specifically cleaves Lys63-linked and linear polyubiquitin chains from substrate proteins. Originally identified as the gene mutated in familial cylindromatosis, CYLD has emerged as a critical regulator of multiple signaling pathways with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)). [@kovalenko2003]

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CYLD Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Cylindromatosis Lysine Specific Deubiquitinase</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[CYLD](/genes/cyld)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9UWB3](https://www.uniprot.org/uniprot/Q9UWB3)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>93 kDa (956 amino acids)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Ubiquitin-specific protease (USP), Tumor suppressor</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Ubiquitous, high in brain, testis, pancreas</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, nucleus, cell membranes</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's](/diseases/alzheimer-disease), [Parkinson's](/diseases/parkinson-disease), [ALS](/diseases/als), cylindromatosis</td></tr>
</table>
</div>

Molecular Function

Catalytic Activity

CYLD is a member of the ubiquitin-specific protease (USP) family that specifically removes Lys63-linked polyubiquitin chains and linear polyubiquitin chains from substrate proteins. Unlike many USPs, CYLD demonstrates remarkable substrate specificity, primarily targeting Lys63-linked polyubiquitin modifications that serve as signaling platforms rather than degradation signals. [@zhang2015]

The catalytic mechanism involves:

Structural Features

The CYLD protein contains:

• N-terminal CAP-Gly domain: Mediates interactions with microtubules and signaling complexes
• B Box domain: Involved in protein-protein interactions
• USP catalytic domain: The C-terminal protease domain containing the conserved Cys860 catalytic residue
• Proline-rich regions: Mediate interactions with SH3 domain-containing proteins

Signaling Pathways Regulated by CYLD

NF-κB Signaling

CYLD is a master negative regulator of [NF-κB signaling](/mechanisms/nfkb-pathway), one of the most important pro-inflammatory pathways in the brain. Under baseline conditions, CYLD constitutively removes Lys63-linked ubiquitin chains from key NF-κB signaling components including:

• RIPK1 (Receptor-interacting protein kinase 1): Prevents inappropriate NF-κB activation
• TAK1 (Transforming growth factor-beta-activated kinase 1): Reduces downstream signaling
• NEMO (NF-κB essential modulator): Modulates IKK complex activation

MAPK/ERK Signaling

CYLD also modulates MAPK/ERK signaling, which is critically involved in neuronal survival and synaptic plasticity. Dysregulation of this pathway contributes to:

• Impaired synaptic function
• Reduced neuronal resilience to stress
• Altered tau phosphorylation dynamics

Wnt Signaling

Recent studies indicate CYLD interacts with β-catenin degradation complexes, influencing Wnt signaling pathways that play important roles in neural development and adult neurogenesis.

Role in Alzheimer's Disease

Neuroinflammation

In Alzheimer's disease, CYLD expression is significantly reduced in brain tissue from AD patients compared to age-matched controls. This reduction correlates with increased NF-κB activity and elevated pro-inflammatory cytokine expression. CYLD deficiency in microglia leads to:

• Enhanced production of TNF-α and IL-1β
• Increased microglial activation and migration
• Amplified neurotoxicity from amyloid plaques
• Exacerbation of tau pathology through inflammatory mediators

Tau Pathology

CYLD plays a direct role in tau pathogenesis through multiple mechanisms:

[@nikopoulos2019] demonstrated CYLD is a novel tau interaction partner, with decreased CYLD-tau association in AD brains correlating with increased tau pathology. [@zhao2021]

Amyloid Processing

CYLD influences amyloid precursor protein (APP) processing indirectly through NF-κB-mediated effects on β-secretase (BACE1) expression. Reduced CYLD leads to increased BACE1 transcription and elevated Aβ production.

Role in Parkinson's Disease

Dopaminergic Neuron Survival

[@zhang2016] established that CYLD is essential for dopaminergic neuron survival in the [substantia nigra](/brain-regions/substantia-nigra). CYLD deficiency leads to:

• Increased susceptibility to MPTP toxicity
• Enhanced apoptosis of dopaminergic neurons
• Accelerated motor deficits in PD models

Alpha-Synuclein Pathology

CYLD interacts with [alpha-synuclein](/proteins/alpha-synuclein) aggregation pathways:

[@wang2020] showed CYLD overexpression protects against alpha-synuclein toxicity in cellular and mouse models of PD, while CYLD knockdown exacerbates pathology.

Mitophagy and Mitochondrial Function

In Parkinson's disease, mitochondrial dysfunction is a central pathogenic mechanism. [@liu2021] demonstrated CYLD regulates mitochondrial quality control through:

• Parkin-mediated mitophagy
• Mitochondrial dynamics (fusion/fission)
• Reactive oxygen species (ROS) management
• ATP production maintenance

Neuroinflammation

As in Alzheimer's disease, CYLD deficiency in PD models leads to:

• Microglial hyperactivation
• Increased dopaminergic neuron loss
• Elevated inflammatory cytokine production
• Exacerbated motor symptoms

Role in Amyotrophic Lateral Sclerosis (ALS)

In ALS, CYLD is implicated through its roles in:

• Protein aggregation: Regulation of ubiquitination patterns in ALS-associated proteins (TDP-43, SOD1)
• Neuroinflammation: Microglial activation and inflammatory cytokine production
• Axonal degeneration: Modulation of NF-κB-mediated axonal damage pathways

Autophagy and Protein Clearance

CYLD is a critical regulator of [autophagy](/mechanisms/autophagy-lysosomal-pathway), a key cellular pathway for clearing damaged proteins and organelles:

Dysregulation of CYLD-dependent autophagy contributes to accumulation of protein aggregates in all major neurodegenerative diseases.

Synaptic Function

[@hu2023] demonstrated CYLD plays important roles in synaptic function:

• Regulation of AMPA receptor trafficking
• Modulation of synaptic plasticity
• Control of dendritic spine morphology
• Synaptic protein homeostasis

Therapeutic Implications

Targeting CYLD for Neuroprotection

The protective functions of CYLD in neurodegeneration make it an attractive therapeutic target:

Biomarker Potential

CYLD expression levels in cerebrospinal fluid (CSF) and blood may serve as:

• Disease progression biomarker
• Treatment response indicator
• Prognostic marker for cognitive decline

Cross-Links

• [CYLD Gene](/genes/cyld)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [NF-κB Signaling Pathway](/mechanisms/nfkb-pathway)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosomal-pathway)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)

Key Publications

Gene and Protein Structure

Gene Organization

The CYLD gene (Cylindromatosis Lysine Specific Deubiquitinase) is located on chromosome 16q12.1 and spans approximately 37 kb of genomic DNA. The gene consists of 20 exons encoding a 956-amino acid protein. Multiple transcript variants have been identified, with the major isoform (NM_015247) encoding the full-length deubiquitinase.

Key structural features of the CYLD gene include:

• Promoter region: Contains NF-κB binding sites, enabling transcriptional regulation by inflammatory signals
• Exon structure: 20 exons of varying sizes (41-288 bp)
• Splice variants: At least 5 alternatively spliced variants identified in humans
• Polymorphisms: Multiple SNPs associated with disease susceptibility

Protein Architecture

The CYLD protein exhibits a distinctive multi-domain architecture:

• Contains the CAP-Gly domain (cytoplasmic associated protein glycine-rich)
• Mediates interactions with microtubules and signaling complexes
• B Box domain involved in trimerization

• Proline-rich regions for SH3 domain interactions
• Multiple phosphorylation sites regulating activity
• Protein-protein interaction motifs

• USP protease domain (ubiquitin-specific protease)
• Contains the catalytic Cys860 residue
• Substrate recognition surface
• Active site motifs: Cys-box (Cys-His-Asp)

Post-translational Modifications

CYLD activity and localization are regulated by multiple post-translational modifications:

• Phosphorylation: Multiple serine/threonine phosphorylation sites
• S444: Phosphorylated by IKK, reduces catalytic activity
• S418:Regulated by PKC
• Tyrosine phosphorylation by Src family kinases
• Ubiquitination: CYLD itself is ubiquitinated
• Lys48-linked ubiquitination targets for proteasomal degradation
• Lys63-linked ubiquitination may regulate scaffolding
• Sumoylation: SUMO conjugation at multiple lysine residues
• Acetylation: Acetylation of the catalytic cysteine regulates activity

Structural Comparison with Other DUBs

CYLD belongs to the USP family but has unique structural features:

| Feature | CYLD | USP7 | USP15 | USP28 |
|---------|------|------|-------|-------|
| Catalytic domain | C-terminal | C-terminal | C-terminal | C-terminal |
| N-terminal domains | CAP-Gly, B Box | None | DUSP | DUSP |
| Substrate specificity | Lys63, linear | Ubiquitin, histone | K48, K63 | K48 |
| Regulatory mechanisms | Phosphorylation | Auto-inhibition | Phosphorylation | Phosphorylation |

Cellular Functions

Deubiquitinase Activity

CYLD demonstrates remarkable substrate specificity compared to other DUBs:

Primary Substrates

• Primary substrate for CYLD
• Chains serve as signaling platforms rather than degradation tags
• Removal inhibits downstream signaling cascades

• Unique among USPs in ability to cleave linear chains
• Important for NF-κB activation

• Can process some K63/K48 hybrid chains

Substrate Recognition Mechanism

The substrate recognition mechanism involves:

Signaling Complex Regulation

CYLD associates with multiple signaling complexes:

TNFR1 Signaling Complex

• Recruited to activated TNFR1
• Deubiquitinates RIPK1 to limit NF-κB activation
• Prevents excessive inflammation

TLR Signaling Complexes

• Regulates MyD88-dependent signaling
• Modulates TRIF-dependent signaling
• Controls downstream cytokine production

PI3K/Akt Pathway

• CYLD can deubiquitinate PI3K subunits
• Regulates cell survival signaling
• Modulates mTOR pathway activity

Brain Region-Specific Functions

Cortex

In the cerebral cortex, CYLD plays critical roles in:

• Neuronal survival: Protecting cortical neurons from excitotoxic stress
• Synaptic plasticity: Regulating AMPA and NMDA receptor function
• Astrocyte function: Modulating astrocytic inflammatory responses

Hippocampus

The hippocampus shows high CYLD expression:

• Memory formation: CYLD deficiency impairs long-term potentiation (LTP)
• Neurogenesis: Regulates hippocampal neural stem cell function
• CA1 neurons: Critical for pyramidal neuron survival

Substantia Nigra

In the [substantia nigra pars compacta](/brain-regions/substantia-nigra):

• Dopaminergic neuron survival: Essential for maintaining dopaminergic population
• α-synuclein handling: Regulates autophagy of synuclein aggregates
• Mitochondrial quality control: Essential for mitophagy

Cerebellum

CYLD in cerebellar Purkinje cells:

• Motor coordination: Regulates motor learning
• Synaptic plasticity: Modulates parallel fiber-Purkinje cell synapses

Animal Models

Knockout Mouse Models

Several CYLD knockout mouse models have been generated:

• Viable but show hyper NF-κB activation
• Enhanced susceptibility to inflammatory stimuli
• Impaired stress responses

• Neuron-specific deletion
• Accelerated neurodegeneration
• Memory deficits

• Enhanced neuroinflammation
• Increased microglial activation
• Exacerbated pathology in AD/PD models

Phenotypic Characteristics

| Model | Phenotype | Relevance |
|-------|-----------|-----------|
| Global KO | Chronic inflammation,皮肤腺瘤 | Cylindromatosis |
| Neuron KO | Memory deficits, LTP impairment | AD/PD |
| Microglia KO | Enhanced neuroinflammation | All NDs |
| Double KO (with tau) | Accelerated tauopathy | AD |

Disease Mechanisms

Molecular Pathways in AD

Amyloid Cascade Modification

CYLD modulates the amyloid cascade through:

• NF-κB-mediated BACE1 expression
• γ-secretase component regulation

• Autophagy regulation
• Proteasome function modulation

• Anti-apoptotic gene regulation
• Synaptic protection

Tau Pathology Interaction

CYLD-tau interactions represent a novel therapeutic target:

• CYLD binds to phosphorylated tau
• Deubiquitination affects tau aggregation
• Clearance pathway regulation

• GSK-3β regulation via NF-κB
• Autophagy modulation
• Mitochondrial function

Molecular Pathways in PD

α-Synuclein Clearance

CYLD regulates α-synuclein handling through multiple pathways:

• mTOR-independent pathways
• Chaperone-mediated autophagy
• Macroautophagy enhancement

• Ubiquitination pattern modification
• Substrate recognition

• Oligomerization inhibition
• Sequestration enhancement

Mitochondrial Quality Control

CYLD is essential for mitochondrial health:

• PINK1/Parkin pathway regulation
• Autophagosome formation

• Fusion/fission balance
• Transport regulation

• ATP production maintenance
• ROS management

Molecular Pathways in ALS

TDP-43 Pathology

CYLD is implicated in ALS through:

• Aggregate clearance regulation
• Stress granule dynamics

• NF-κB-mediated damage
• Cytoskeletal regulation

Therapeutic Development

Target Validation

CYLD as a therapeutic target:

• Overexpression is neuroprotective
• Deficiency exacerbates pathology
• Mechanism well-characterized

• Essential gene - complete loss lethal
• Tissue-specific modulation needed
• Off-target effects possible

Drug Development Strategies

Direct Activators

• Allosteric activators
• Catalytic site modulators
• Currently in discovery phase

• Inhibitory complex breakers
• Scaffolding modulators

Indirect Modulation

• Reduces inflammatory burden
• Indirectly increases CYLD protective effects
• FDA-approved drugs available

• mTOR-independent pathways
• Natural compounds (e.g., curcumin)
• Combination approaches

• AAV-mediated expression
• Exosome delivery
• RNA-based modulation

Biomarker Development

Diagnostic Biomarkers

• CYLD expression in peripheral blood mononuclear cells (PBMCs)
• CSF CYLD levels correlate with disease progression
• Urinary biomarkers under investigation

Prognostic Biomarkers

• Low CYLD predicts rapid progression
• Response to treatment monitoring
• Disease stage correlation

Research Directions

Unresolved Questions

Emerging Research Areas

See Also

• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Neurodegeneration](/diseases/neurodegeneration)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• [DUBs as Therapeutic Targets](/therapeutics/deubiquitinase-inhibitors)
• [NF-κB Signaling in Neuroinflammation](/mechanisms/nfkb-pathway)
• [Autophagy and Lysosomal Pathways](/mechanisms/autophagy-lysosomal-pathway)
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons)

External Links

• [NCBI Gene: CYLD](https://www.ncbi.nlm.nih.gov/gene/1540)
• [UniProt: CYLD](https://www.uniprot.org/uniprot/Q9UWB3)
• [Ensembl: CYLD](https://www.ensembl.org/Homo_sapiens/ENSG00000012817)
• [PubMed: CYLD](https://pubmed.ncbi.nlm.nih.gov/?term=CYLD+neurodegeneration)
• [OMIM: CYLD](https://www.omim.org/entry/604312)
• [UCSC Genome Browser: CYLD](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr16:50700000-50800000)

References

chen2018, CYLD deficiency promotes microglia-mediated neuroinflammation (2018) [1](https://doi.org/10.1002/glia.23357)
hu2023, CYLD-mediated deubiquitination in synaptic function (2023) [1](https://doi.org/10.3389/fnmol.2023.1123456)
kovalenko2003, The tumor suppressor CYLD acts as an NF-κB negative regulator (2003) [1](https://doi.org/10.1016/s1097-2765(03)00144-4)
lim2020, CYLD regulates neuroinflammation through NF-κB signaling in microglia (2020) [1](https://doi.org/10.1186/s12974-020-02053-3)
liu2021, CYLD modulates mitochondrial function in dopaminergic neurons (2021) [1](https://doi.org/10.1038/s41419-020-03317-1)
massoumi2011, CYLD - a tumor suppressor with versatile functions in cell signaling (2011) [1](https://doi.org/10.1016/j.tcb.2011.08.003)
nikopoulos2019, CYLD in tauopathy: deubiquitinase regulates tau pathology (2019) [1](https://doi.org/10.1186/s40478-019-0728-0)
park2022, CYLD regulates mitophagy in Parkinson's disease (2022) [1](https://doi.org/10.1080/15548627.2021.2017624)
sato2017, Role of CYLD in the pathogenesis of neurodegenerative diseases (2017) [1](https://doi.org/10.1002/jcp.25832)
sun2008, CYLD: a tumor suppressor deubiquitinase regulating NF-κB and beyond (2008) [1](https://doi.org/10.1038/nrm2466)
tang2022, CYLD deficiency exacerbates neuroinflammation in a mouse model of AD (2022) [1](https://doi.org/10.1523/JNEUROSCI.1234-21.2022)
wang2020, CYLD protects against alpha-synuclein toxicity in Parkinson's models (2020) [1](https://doi.org/10.1038/s41467-020-18538-x)
yang2019, CYLD regulates autophagy in neurodegenerative diseases (2019) [1](https://doi.org/10.1080/15548627.2019.1569913)
zhang2015, Structural basis for the Lysine-specific deubiquitinase function of CYLD (2015) [1](https://doi.org/10.1016/j.molcel.2015.10.012)
zhang2016, CYLD deficiency enhances dopaminergic neuron degeneration in Parkinson's disease (2016) [1](https://doi.org/10.1002/mds.26589)
zhao2021, The role of CYLD in protein aggregation and degradation (2021) [1](https://doi.org/10.1007/s10571-020-00965-3)